Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Quell Therapeutics to Present at Upcoming Investor Conferences in 2022 | ||
| By: PR Newswire Association LLC. - 22 Nov 2022 | Back to overview list |
|
|
LONDON and BOSTON, Nov. 22, 2022 /PRNewswire/ -- Quell Therapeutics Ltd ("Quell"), a leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that management will participate in two upcoming investor conferences:
About Quell Therapeutics Quell Therapeutics is a world leader in developing engineered T-regulatory (Treg) cell therapies that aim to harness, direct and optimize their immune suppressive properties to address serious medical conditions driven by the immune system. The Company is leveraging its pioneering phenotype lock technology, unique multi-modular platform and integrated manufacturing capabilities to design and develop a pipeline of highly engineered Treg cell therapies with greater potential for persistence, potency and stability than earlier generations of Treg cell therapy approaches. Quell's lead candidate QEL-001 is being developed to induce operational tolerance following liver transplantation, with the potential to protect the post-transplant liver without the need for chronic immunosuppressive medications. Quell is also advancing additional programs in neuroinflammatory and autoimmune diseases. www.quell-tx.com. Contacts Luke Henry, Chief Business Officer Media: Mark Swallow, Frazer Hall, Eleanor Perkin Investors: Christina Tartaglia
|
||
|
||
 | Back to overview list | |
View original content: